Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA

Aura Biosciences, Inc.

Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.
Net loss $22.1M Q4 2023 and $76.4M full year 2023 vs $16.6M and $58.8M prior year.
R&D expenses $65.2M for FY2023, up from $42.2M due to Phase 3 start and manufacturing costs.
Global Phase 3 CoMpass trial for small choroidal melanoma actively enrolling under FDA SPA; Phase 2 showed 80% tumor control, 90% vision preservation.
Phase 1 bladder cancer trial ongoing; data expected mid-2024; first patient showed complete response after single dose with light activation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2023.

Period: fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Aura Biosciences, Inc., issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.